Crinetics Pharmaceuticals, INC

Crinetics Pharmaceuticals announced a definitive agreement to be acquired by Vertex Pharmaceuticals for approximately $10.0 billion, alongside reporting strong second-quarter 2026 financial results driven by PALSONIFY sales.

Crinetics Pharmaceuticals announces a definitive merger agreement with Vertex Pharmaceuticals, including non-compete agreements with key employees.

Vertex Pharmaceuticals announced its definitive agreement to acquire Crinetics Pharmaceuticals for approximately $10 billion in cash, aiming to bolster its pipeline with endocrinology assets.

Crinetics Pharmaceuticals announced first-quarter 2026 financial results, highlighting $10.3 million in net product revenue for PALSONIFY and providing business updates on clinical trials and regulatory approvals.

Crinetics Pharmaceuticals announces the departure of Jeff Knight as Chief Development and Operating Officer, transitioning to an independent consultant role.

Crinetics Pharmaceuticals announces the resignation of Chief Development and Operating Officer Jeff Knight, effective April 10, 2026, citing no disagreement with company operations.

Crinetics Pharmaceuticals reports strong Q1 2026 results driven by PALSONIFY commercialization, with significant revenue growth and increased R&D investment.

Crinetics Pharmaceuticals reports FDA approval for PALSONIFY in acromegaly, significant R&D pipeline progress, and increased operating losses in its Q3 2025 filing.

Crinetics Pharmaceuticals reports increased losses driven by accelerated R&D and commercialization efforts, while advancing its lead drug candidates Paltusotine and Atumelnant with positive clinical and regulatory updates.

Crinetics Pharmaceuticals announces its Q1 2025 financial results, showcasing ongoing clinical trials and strategic advancements in its endocrine disease and tumor therapeutics pipeline.

Crinetics Pharmaceuticals reported its Q3 2024 financial results, highlighting progress in clinical trials and a recent NDA submission for paltusotine.

Crinetics Pharmaceuticals reported its financial results for the second quarter of 2024, highlighting progress in its clinical programs and financial position.

Crinetics Pharmaceuticals reports FDA approval for PALSONIFY in acromegaly, marking its transition to a commercial-stage company, alongside pipeline advancements and a strong capital position.

Crinetics Pharmaceuticals provides an update on its clinical-stage endocrine disease therapies, including the submission of a New Drug Application (NDA) to the FDA for paltusotine.

Crinetics Pharmaceuticals amends its lease agreement, files its annual report on Form 10-K, and updates its insider trading policy, outlining key business activities and financial safeguards.

Director Rogerio Vivaldi Coelho has sold 3,000 shares of Crinetics Pharmaceuticals, Inc. common stock for $40 per share, executed under a Rule 10b5-1 trading plan.

Director Stephanie Okey of Crinetics Pharmaceuticals, Inc. (CRNX) reported the sale of common stock totaling 6,890 shares, executed under a Rule 10b5-1 trading plan.

Richard Scott Struthers, Director and President & CEO of Crinetics Pharmaceuticals, Inc., reported significant changes in beneficial ownership of common stock on May 29, 2026.

Jeff E. Knight, Chief Development & Operating Officer of Crinetics Pharmaceuticals, Inc., reported the sale of 85,163 shares of common stock on April 8, 2026, executed under a Rule 10b5-1 trading plan.

Crinetics Pharmaceuticals Director Rogerio Vivaldi Coelho sold 5,000 shares of common stock for approximately $180,740 through a pre-arranged Rule 10b5-1 trading plan.

Crinetics Pharmaceuticals Director Stephanie Okey sold 3,000 shares of common stock for $39.67 each, executed under a pre-arranged 10b5-1 trading plan.

Crinetics Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Shareholders, scheduled for June 18, 2026, to elect directors, ratify auditor selection, and vote on executive compensation.

Crinetics Pharmaceuticals issues a supplement to its proxy statement to correct clerical errors regarding the day of the week for the annual meeting and the deadline for stockholder proposals.

Crinetics Pharmaceuticals will hold its annual stockholders meeting on June 11, 2025, to elect directors, ratify the selection of an independent accounting firm, and conduct an advisory vote on executive compensation.

Crinetics Pharmaceuticals sets June 11, 2025, for its annual stockholder meeting to elect directors, ratify the selection of an independent accounting firm, and conduct an advisory vote on executive compensation.

Crinetics Pharmaceuticals will hold its annual stockholders meeting on June 7, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.

Crinetics Pharmaceuticals will hold its annual meeting of stockholders virtually on June 7, 2024, to vote on director elections, auditor ratification, and executive compensation.

Farallon Capital Management, L.L.C. and associated entities have reported beneficial ownership of 8.5% of Crinetics Pharmaceuticals, Inc. common stock as of June 30, 2026.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 7.8% of Crinetics Pharmaceuticals, Inc. common stock as of March 31, 2026.

Driehaus Capital Management LLC has filed an amendment to its Schedule 13G, reporting a decrease in its beneficial ownership of Crinetics Pharmaceuticals, Inc. common stock to 6.11% as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.19% of Crinetics Pharmaceuticals Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 0% beneficial ownership in Crinetics Pharmaceuticals Inc. following an internal realignment.

Farallon Capital and its affiliates have filed an amended Schedule 13G for Crinetics Pharmaceuticals, Inc., reporting an 8.5% beneficial ownership and detailing recent management changes within Farallon.